| Inhibikase: Potential To Improve Current Treatment Options For PAH Patients | 11/19 13:32 | seekingalpha.com |
| Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity | 11/14 08:37 | globenewswire.com |
| Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension | 10/21 09:05 | globenewswire.com |
| Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension | 10/09 09:18 | globenewswire.com |
| Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript | 08/15 18:13 | seekingalpha.com |
| Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity | 08/14 16:25 | globenewswire.com |
| Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 | 08/07 08:00 | globenewswire.com |
| Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease | 06/17 08:05 | globenewswire.com |
| Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs | 06/05 08:05 | globenewswire.com |
| Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million | 05/20 08:01 | globenewswire.com |